Skip to Content

Ravicti Approval History

  • FDA approved: Yes (First approved February 1st, 2013)
  • Brand name: Ravicti
  • Generic name: glycerol phenylbutyrate
  • Dosage form: Oral Liquid
  • Company: Hyperion Therapeutics
  • Treatment for: Urea Cycle Disorders

Ravicti (glycerol phenylbutyrate) is a nitrogen-binding agent for the chronic management of patients with urea cycle disorders.

Development History and FDA Approval Process for Ravicti

Feb  1, 2013Approval FDA Approves Ravicti for the Chronic Management of Some Urea Cycle Disorders

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.